Icon Plc $ICLR is Hyperion Capital Advisors LP’s 8th Largest Position

Hyperion Capital Advisors LP raised its position in Icon Plc (NASDAQ:ICLR) by 34.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 66,021 shares of the medical research company’s stock after buying an additional 16,757 shares during the period. Icon comprises 5.9% of Hyperion Capital Advisors LP’s investment portfolio, making the stock its 8th biggest position. Hyperion Capital Advisors LP owned approximately 0.08% of Icon worth $12,030,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Toth Financial Advisory Corp purchased a new stake in shares of Icon during the fourth quarter worth about $27,000. Ameriflex Group Inc. purchased a new stake in shares of Icon during the third quarter worth about $33,000. Johnson Financial Group Inc. purchased a new stake in shares of Icon during the third quarter worth about $71,000. Quadrant Capital Group LLC purchased a new stake in shares of Icon during the third quarter worth about $78,000. Finally, Geneos Wealth Management Inc. increased its stake in shares of Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after purchasing an additional 56 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Stock Performance

Icon stock opened at $146.18 on Friday. The firm has a 50 day simple moving average of $121.76 and a 200-day simple moving average of $140.47. Icon Plc has a 1-year low of $66.57 and a 1-year high of $211.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.10 and a quick ratio of 1.10. The stock has a market cap of $11.19 billion, a price-to-earnings ratio of 23.73, a price-to-earnings-growth ratio of 11.84 and a beta of 1.26.

Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, June 17th. The medical research company reported $2.52 earnings per share for the quarter, beating the consensus estimate of $2.47 by $0.05. Icon had a net margin of 5.98% and a return on equity of 9.50%. The business had revenue of $2.11 billion during the quarter, compared to analysts’ expectations of $1.99 billion. During the same quarter in the prior year, the company posted $3.43 EPS. The business’s revenue for the quarter was up 2.5% on a year-over-year basis. On average, analysts expect that Icon Plc will post 9.74 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on ICLR. DA Davidson set a $164.00 target price on shares of Icon in a research note on Monday, June 1st. Zacks Research cut shares of Icon from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 25th. Citigroup boosted their price target on shares of Icon from $120.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, May 29th. Jefferies Financial Group restated a “buy” rating and set a $165.00 price target on shares of Icon in a research report on Friday, May 29th. Finally, BMO Capital Markets boosted their price target on shares of Icon from $130.00 to $160.00 and gave the stock an “outperform” rating in a research report on Friday, May 29th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Icon has a consensus rating of “Hold” and a consensus target price of $156.44.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.